Therapeutic Potential of EVs: Targeting Cardiovascular Diseases

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2023 Jul 29

PMID 37509546

Authors

Javier Laura Frances

Christina Pagiatakis

Vittoria Di Mauro

Montserrat Climent

Affiliations

Soon will be listed here.

Abstract

Due to their different biological functions, extracellular vesicles (EVs) have great potential from a therapeutic point of view. They are released by all cell types, carrying and delivering different kinds of biologically functional cargo. Under pathological events, cells can increase their secretion of EVs and can release different amounts of cargo, thus making EVs great biomarkers as indicators of pathological progression. Moreover, EVs are also known to be able to transport and deliver cargo to different recipient cells, having an important role in cellular communication. Interestingly, EVs have recently been explored as biological alternatives for the delivery of therapeutics, being considered natural drug delivery carriers. Because cardiovascular disorders (CVDs) are the leading cause of death worldwide, in this review, we will discuss the up-to-date knowledge regarding the biophysical properties and biological components of EVs, focusing on myocardial infarction, diabetic cardiomyopathy, and sepsis-induced cardiomyopathy, three very different types of CVDs.

Citing Articles

Exosomes derived from TNF-α preconditioned bone marrow mesenchymal stem cells alleviate cisplatin-induced ototoxicity in mice.

Li W, Yang T, Zhang Z, Peng A, Wang Q Int J Med Sci. 2025; 22(5):1215-1222.

PMID: 40027193 PMC: 11866538. DOI: 10.7150/ijms.104121.

A Simplified Method for the Isolation of Extracellular Vesicles from Probiotic Bacteria and Their Characterization.

Sawant H, Bihl J, Borthakur A Int J Mol Sci. 2025; 26(3).

PMID: 39940832 PMC: 11817318. DOI: 10.3390/ijms26031058.

Engineering extracellular vesicles for targeted therapeutics in cardiovascular disease.

Fu E, Pan K, Li Z Front Cardiovasc Med. 2025; 11:1503830.

PMID: 39749310 PMC: 11693616. DOI: 10.3389/fcvm.2024.1503830.

Living biodrugs and how tissue source influences mesenchymal stem cell therapeutics for heart failure.

Shah S, Nawaz H, Qazi M, Jain H, Lucke-Wold B World J Cardiol. 2024; 16(11):619-625.

PMID: 39600993 PMC: 11586726. DOI: 10.4330/wjc.v16.i11.619.

Extracellular Vesicles in Diabetic Cardiomyopathy-State of the Art and Future Perspectives.

Zygmunciak P, Strozna K, Blazowska O, Mrozikiewicz-Rakowska B Int J Mol Sci. 2024; 25(11).

PMID: 38892303 PMC: 11172920. DOI: 10.3390/ijms25116117.

References

Koudelka S, Turanek J . Liposomal paclitaxel formulations. J Control Release. 2012; 163(3):322-34. DOI: 10.1016/j.jconrel.2012.09.006. View

Zanotti-Cavazzoni S, Hollenberg S . Cardiac dysfunction in severe sepsis and septic shock. Curr Opin Crit Care. 2009; 15(5):392-7. DOI: 10.1097/MCC.0b013e3283307a4e. View

El Andaloussi S, Mager I, Breakefield X, Wood M . Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013; 12(5):347-57. DOI: 10.1038/nrd3978. View

Thakur A, Sidu R, Zou H, Alam M, Yang M, Lee Y . Inhibition of Glioma Cells' Proliferation by Doxorubicin-Loaded Exosomes via Microfluidics. Int J Nanomedicine. 2020; 15:8331-8343. PMC: 7605152. DOI: 10.2147/IJN.S263956. View

Hegyesi H, Pallinger E, Mecsei S, Hornyak B, Kovacshazi C, Brenner G . Circulating cardiomyocyte-derived extracellular vesicles reflect cardiac injury during systemic inflammatory response syndrome in mice. Cell Mol Life Sci. 2022; 79(2):84. PMC: 8776681. DOI: 10.1007/s00018-021-04125-w. View

Mahidhara R, Billiar T . Apoptosis in sepsis. Crit Care Med. 2000; 28(4 Suppl):N105-13. DOI: 10.1097/00003246-200004001-00013. View

van der Koog L, Gandek T, Nagelkerke A . Liposomes and Extracellular Vesicles as Drug Delivery Systems: A Comparison of Composition, Pharmacokinetics, and Functionalization. Adv Healthc Mater. 2021; 11(5):e2100639. PMC: 11468589. DOI: 10.1002/adhm.202100639. View

Deng S, Zhou X, Ge Z, Song Y, Wang H, Liu X . Exosomes from adipose-derived mesenchymal stem cells ameliorate cardiac damage after myocardial infarction by activating S1P/SK1/S1PR1 signaling and promoting macrophage M2 polarization. Int J Biochem Cell Biol. 2019; 114:105564. DOI: 10.1016/j.biocel.2019.105564. View

Muthu S, Sukumaran V, Sundararajan V . Editorial: Understanding Molecular Mechanisms in Diabetic Cardiomyopathy (DCM). Front Cardiovasc Med. 2022; 9:965650. PMC: 9282885. DOI: 10.3389/fcvm.2022.965650. View

10.

Dewanjee S, Vallamkondu J, Kalra R, John A, Reddy P, Kandimalla R . Autophagy in the diabetic heart: A potential pharmacotherapeutic target in diabetic cardiomyopathy. Ageing Res Rev. 2021; 68:101338. DOI: 10.1016/j.arr.2021.101338. View

11.

Lin H, Wang W, Lee M, Meng Q, Ren H . Current Status of Septic Cardiomyopathy: Basic Science and Clinical Progress. Front Pharmacol. 2020; 11:210. PMC: 7062914. DOI: 10.3389/fphar.2020.00210. View

12.

Huang J, Chang C, Kuo C, Huang K, Sokal E, Chen K . Exosomal microRNAs miR-30d-5p and miR-126a-5p Are Associated with Heart Failure with Preserved Ejection Fraction in STZ-Induced Type 1 Diabetic Rats. Int J Mol Sci. 2022; 23(14). PMC: 9318774. DOI: 10.3390/ijms23147514. View

13.

Anakor E, Le Gall L, Dumonceaux J, Duddy W, Duguez S . Exosomes in Ageing and Motor Neurone Disease: Biogenesis, Uptake Mechanisms, Modifications in Disease and Uses in the Development of Biomarkers and Therapeutics. Cells. 2021; 10(11). PMC: 8616058. DOI: 10.3390/cells10112930. View

14.

Gilbert R, Krum H . Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet. 2015; 385(9982):2107-17. DOI: 10.1016/S0140-6736(14)61402-1. View

15.

Ginini L, Billan S, Fridman E, Gil Z . Insight into Extracellular Vesicle-Cell Communication: From Cell Recognition to Intracellular Fate. Cells. 2022; 11(9). PMC: 9101098. DOI: 10.3390/cells11091375. View

16.

Zhang J, Lu Y, Mao Y, Yu Y, Wu T, Zhao W . IFN-γ enhances the efficacy of mesenchymal stromal cell-derived exosomes via miR-21 in myocardial infarction rats. Stem Cell Res Ther. 2022; 13(1):333. PMC: 9308256. DOI: 10.1186/s13287-022-02984-z. View

17.

Yin Z, Chen C . Biological Functions and Clinical Prospects of Extracellular Non-Coding RNAs in Diabetic Cardiomyopathy: an Updated Review. J Cardiovasc Transl Res. 2022; 15(3):469-476. DOI: 10.1007/s12265-022-10217-0. View

18.

Ye R, Lin Q, Xiao W, Mao L, Zhang P, Zhou L . miR-150-5p in neutrophil-derived extracellular vesicles associated with sepsis-induced cardiomyopathy in septic patients. Cell Death Discov. 2023; 9(1):19. PMC: 9867758. DOI: 10.1038/s41420-023-01328-x. View

19.

Laura Frances J, Musolino E, Papait R, Pagiatakis C . Non-Coding RNAs in Cell-to-Cell Communication: Exploiting Physiological Mechanisms as Therapeutic Targets in Cardiovascular Pathologies. Int J Mol Sci. 2023; 24(3). PMC: 9916956. DOI: 10.3390/ijms24032205. View

20.

Rezaie J, Rahbarghazi R, Pezeshki M, Mazhar M, Yekani F, Khaksar M . Cardioprotective role of extracellular vesicles: A highlight on exosome beneficial effects in cardiovascular diseases. J Cell Physiol. 2019; 234(12):21732-21745. DOI: 10.1002/jcp.28894. View